Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Hemoglobinand Hematocrit: A Retrospective Analysis (SGLT-2 Inhibitors &Hemoconcentration)
Abstract
Background: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, such as Dapagliflozin and Empagliflozin, are a class of medications used in the management of type 2 diabetes mellitus and, more recently, heart failure and chronic kidney disease. An observed secondary effect of these drugs is an increase in hematocrit (Hct) and hemoglobin (Hb) levels. The mechanisms and clinical significance of these changes are still under investigation. Large cardiovascular outcome trials did not demonstrate a consistent signal for increased thromboembolic events; details on this subject will be mentioned in the discussion section. This study aims to analyze the effect of dapagliflozin and empagliflozin treatment on Hct and Hb in a cohort of 97 patients in our hospital.Methods: We conducted a retrospective analysis of a dataset containing information on 97 patients treated with either Dapagliflozin (n = 58) or Empagliflozin (n = 39). The dataset included baseline and 3–6-month follow-up measurements of Hct and Hb, along with demographic and clinical data such as age, BMI, smoking status, and diabetes mellitus (DM) status. Results: Both Dapagliflozin and Empagliflozin were associated with a numerical increase in mean Hct and Hb levels over a 3–6-month period. The increase in hemoglobin/hematocrit was statistically significant for the Empagliflozin group (p = 0.0107), but not for the Dapagliflozin group (p = 0.0642). There was no statistically significant difference in the magnitude of change…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 97 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.